Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Skylands Capital LLC

Skylands Capital LLC grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 36.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 504,500 shares of the company's stock after purchasing an additional 134,150 shares during the quarter. Skylands Capital LLC owned approximately 0.10% of Elanco Animal Health worth $6,109,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hardman Johnston Global Advisors LLC raised its holdings in shares of Elanco Animal Health by 22.5% during the 4th quarter. Hardman Johnston Global Advisors LLC now owns 1,566,430 shares of the company's stock worth $18,969,000 after acquiring an additional 288,160 shares in the last quarter. New World Advisors LLC increased its holdings in Elanco Animal Health by 19.8% during the 4th quarter. New World Advisors LLC now owns 30,900 shares of the company's stock worth $374,000 after purchasing an additional 5,100 shares during the period. Legacy Capital Group California Inc. purchased a new position in shares of Elanco Animal Health during the fourth quarter valued at $194,000. Handelsbanken Fonder AB increased its position in Elanco Animal Health by 11.9% during the 4th quarter. Handelsbanken Fonder AB now owns 139,600 shares of the company's stock valued at $1,691,000 after purchasing an additional 14,800 shares during the period. Finally, Private Advisor Group LLC increased its holdings in Elanco Animal Health by 6.3% during the fourth quarter. Private Advisor Group LLC now owns 148,763 shares of the company's stock valued at $1,802,000 after buying an additional 8,848 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Barclays cut their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday. Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective for the company. Morgan Stanley reduced their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday. UBS Group reduced their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $15.57.

Elanco Animal Health Trading Down 1.8 %

Shares of NYSE:ELAN traded down $0.21 during mid-day trading on Thursday, reaching $10.93. 3,696,771 shares of the company were exchanged, compared to its average volume of 4,908,907. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of 27.31, a P/E/G ratio of 2.50 and a beta of 1.42. The firm's 50-day simple moving average is $11.72 and its 200 day simple moving average is $13.05. Elanco Animal Health Incorporated has a 1 year low of $10.20 and a 1 year high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 earnings per share. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.